{"id":"https://openalex.org/W2131933367","doi":"https://doi.org/10.1158/1535-7163.mct-11-1027","title":"MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo","display_name":"MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo","publication_year":2012,"publication_date":"2012-06-08","ids":{"openalex":"https://openalex.org/W2131933367","doi":"https://doi.org/10.1158/1535-7163.mct-11-1027","mag":"2131933367","pmid":"https://pubmed.ncbi.nlm.nih.gov/22679110"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-11-1027","doi":"https://doi.org/10.1158/1535-7163.mct-11-1027","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-11-1027","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"David W. Jenkins","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David W. Jenkins","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077757906","display_name":"Sarah J. Ross","orcid":"https://orcid.org/0000-0001-8759-1728","observed_orcids":["https://orcid.org/0000-0001-8759-1728"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sarah Ross","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031881855","display_name":"Margaret H. Veldman-Jones","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Margaret Veldman-Jones","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034901985","display_name":"Ian N. Foltz","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ian N. Foltz","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082830770","display_name":"Brandon C. Clavette","orcid":"https://orcid.org/0000-0003-0340-4396","observed_orcids":["https://orcid.org/0000-0003-0340-4396"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Brandon C. Clavette","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031833310","display_name":"Kathy Manchulenko","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kathy Manchulenko","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032576859","display_name":"Cath Eberlein","orcid":"https://orcid.org/0000-0002-7357-7789","observed_orcids":["https://orcid.org/0000-0002-7357-7789"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cath Eberlein","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001053254","display_name":"Jane Kendrew","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jane Kendrew","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065043987","display_name":"Philip Petteruti","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Philip Petteruti","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058484248","display_name":"Song Cho","orcid":"https://orcid.org/0009-0007-6119-5269","observed_orcids":["https://orcid.org/0009-0007-6119-5269"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Song Cho","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088256361","display_name":"Melissa M. Damschroder","orcid":"https://orcid.org/0000-0001-9453-6532","observed_orcids":["https://orcid.org/0000-0001-9453-6532"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Melissa Damschroder","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100784878","display_name":"Li Peng","orcid":"https://orcid.org/0000-0001-5358-6736","observed_orcids":["https://orcid.org/0000-0001-5358-6736"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Li Peng","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072961963","display_name":"Dawn Baker","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dawn Baker","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027141514","display_name":"Neil R. Smith","orcid":"https://orcid.org/0000-0002-0023-4398","observed_orcids":["https://orcid.org/0000-0002-0023-4398"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Neil R. Smith","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048485800","display_name":"Hazel M. Weir","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hazel M. Weir","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108761410","display_name":"David C. Blakey","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David C. Blakey","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014557125","display_name":"Vahe Bedian","orcid":"https://orcid.org/0000-0002-0685-5451","observed_orcids":["https://orcid.org/0000-0002-0685-5451"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vahe Bedian","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5044054725","display_name":"Simon T. Barry","orcid":"https://orcid.org/0000-0002-8511-0588","observed_orcids":["https://orcid.org/0000-0002-8511-0588"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Simon T. Barry","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology iMED, AstraZeneca R&D Boston, Waltham, Massachusetts; 2Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Amgen, Burnaby, British Columbia, Canada; and 4MedImmune, One MedImmune Way, Gaithersburg, Maryland","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.1409,"has_fulltext":false,"cited_by_count":51,"citation_normalized_percentile":{"value":0.88363622,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"11","issue":"8","first_page":"1650","last_page":"1660"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10268","display_name":"Developmental Biology and Gene Regulation","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11469","display_name":"Lymphatic System and Diseases","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/delta-like-ligand-4","display_name":"DLL4","score":0.8899999856948853},{"id":"https://openalex.org/keywords/notch1","display_name":"Notch1","score":0.8169999718666077},{"id":"https://openalex.org/keywords/therapeutic-antibodies","display_name":"therapeutic antibodies","score":0.7289999723434448},{"id":"https://openalex.org/keywords/dll4-notch-signaling","display_name":"Dll4-Notch signaling","score":0.8009999990463257},{"id":"https://openalex.org/keywords/angiogenesis","display_name":"angiogenesis","score":0.859000027179718},{"id":"https://openalex.org/keywords/endothelial-function","display_name":"endothelial function","score":0.7789999842643738},{"id":"https://openalex.org/keywords/tumor-angiogenesis","display_name":"tumor angiogenesis","score":0.9300000071525574}],"concepts":[{"id":"https://openalex.org/C2780394083","wikidata":"https://www.wikidata.org/wiki/Q539568","display_name":"Angiogenesis","level":2,"score":0.7825850248336792},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.6514668464660645},{"id":"https://openalex.org/C161879069","wikidata":"https://www.wikidata.org/wiki/Q904082","display_name":"Notch signaling pathway","level":3,"score":0.6372016668319702},{"id":"https://openalex.org/C2777834122","wikidata":"https://www.wikidata.org/wiki/Q5939177","display_name":"Human umbilical vein endothelial cell","level":4,"score":0.5752748847007751},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5661855340003967},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.5183266401290894},{"id":"https://openalex.org/C123012128","wikidata":"https://www.wikidata.org/wiki/Q5376430","display_name":"Endothelial stem cell","level":3,"score":0.47699645161628723},{"id":"https://openalex.org/C2777411675","wikidata":"https://www.wikidata.org/wiki/Q1232438","display_name":"Umbilical vein","level":3,"score":0.472251832485199},{"id":"https://openalex.org/C195616568","wikidata":"https://www.wikidata.org/wiki/Q128711","display_name":"Epitope","level":3,"score":0.4604538083076477},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.440912127494812},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.43706804513931274},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.34991663694381714},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.34707406163215637},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.33650118112564087},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.3283594846725464},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2408936619758606},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.11643454432487488},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D002460","descriptor_name":"Cell Line","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008565","descriptor_name":"Membrane Proteins","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D008565","descriptor_name":"Membrane Proteins","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D009389","descriptor_name":"Neovascularization, Pathologic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011485","descriptor_name":"Protein Binding","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015398","descriptor_name":"Signal Transduction","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D016513","descriptor_name":"Mice, SCID","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018604","descriptor_name":"Epitope Mapping","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018919","descriptor_name":"Neovascularization, Physiologic","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D042783","descriptor_name":"Endothelial Cells","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D042783","descriptor_name":"Endothelial Cells","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D047908","descriptor_name":"Intracellular Signaling Peptides and Proteins","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D047908","descriptor_name":"Intracellular Signaling Peptides and Proteins","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051880","descriptor_name":"Receptors, Notch","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1158/1535-7163.mct-11-1027","doi":"https://doi.org/10.1158/1535-7163.mct-11-1027","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-11-1027","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:22679110","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22679110","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":35,"referenced_works":["https://openalex.org/W1554383529","https://openalex.org/W1660631781","https://openalex.org/W1977514835","https://openalex.org/W1977962361","https://openalex.org/W1992133600","https://openalex.org/W1997801717","https://openalex.org/W2006961900","https://openalex.org/W2012483332","https://openalex.org/W2014016903","https://openalex.org/W2019688531","https://openalex.org/W2028561648","https://openalex.org/W2031191981","https://openalex.org/W2040827891","https://openalex.org/W2045247659","https://openalex.org/W2051319925","https://openalex.org/W2056916102","https://openalex.org/W2067684732","https://openalex.org/W2073465941","https://openalex.org/W2074575987","https://openalex.org/W2075773133","https://openalex.org/W2076274098","https://openalex.org/W2082694975","https://openalex.org/W2089231072","https://openalex.org/W2093498435","https://openalex.org/W2096861436","https://openalex.org/W2100979164","https://openalex.org/W2124396025","https://openalex.org/W2128295200","https://openalex.org/W2134698258","https://openalex.org/W2137175694","https://openalex.org/W2153726848","https://openalex.org/W2154861644","https://openalex.org/W2157930949","https://openalex.org/W2160947862","https://openalex.org/W2168215545"],"related_works":["https://openalex.org/W1998110257","https://openalex.org/W2966960773","https://openalex.org/W3110030570","https://openalex.org/W2349865796","https://openalex.org/W3021227184","https://openalex.org/W2040827891","https://openalex.org/W2117748018","https://openalex.org/W3012204787","https://openalex.org/W181837403","https://openalex.org/W2423432333"],"abstract_inverted_index":{"The":[0,92],"Notch":[1],"signaling":[2,167,227],"pathway":[3],"has":[4,38,119],"been":[5,39,121],"implicated":[6],"in":[7,13,23,41,55,64,141,146,151,171,191],"cell":[8,139,156,195],"fate":[9],"determination":[10],"and":[11,27,44,90,202],"differentiation":[12],"many":[14],"tissues.":[15],"Accumulating":[16],"evidence":[17],"points":[18],"toward":[19],"a":[20,53,59,115,152,159,172,180,192,222],"pivotal":[21],"role":[22],"blood":[24],"vessel":[25,200],"formation,":[26],"the":[28,31,72,86,107,165,204,216],"importance":[29],"of":[30,48,61,71,109,134,148,164,183,206,225],"Delta-like":[32],"ligand":[33],"(Dll)":[34],"4-Notch1":[35],"ligand-receptor":[36],"interaction":[37,50,87],"shown":[40],"both":[42],"physiological":[43],"tumor":[45,56],"angiogenesis.":[46],"Disruption":[47],"this":[49,126],"leads":[51],"to":[52,68,84,95,111,125],"reduction":[54],"growth":[57,140],"as":[58],"result":[60],"an":[62,76],"increase":[63],"nonfunctional":[65],"vasculature":[66],"leading":[67],"poor":[69],"perfusion":[70],"tumor.":[73],"MEDI0639":[74,105,130,143,178,188,220],"is":[75,179,221],"investigational":[77],"human":[78,135,193,199],"therapeutic":[79],"antibody":[80,93],"that":[81,118,219],"targets":[82],"Dll4":[83,89],"inhibit":[85],"between":[88],"Notch1.":[91],"cross-reacts":[94],"cynomolgus":[96],"monkey":[97],"but":[98],"not":[99,120],"mouse":[100],"species":[101],"orthologues.":[102],"In":[103,169,186],"vitro":[104],"inhibits":[106],"binding":[108],"Notch1":[110],"Dll4,":[112],"interacting":[113],"via":[114],"novel":[116],"epitope":[117,127],"previously":[122],"described.":[123],"Binding":[124],"translates":[128],"into":[129],"reversing":[131],"Notch1-mediated":[132],"suppression":[133],"umbilical":[136],"vein":[137],"endothelial":[138,155,174,194],"vitro.":[142],"administration":[144],"resulted":[145],"stimulation":[147],"tubule":[149,184],"formation":[150,201],"three-dimensional":[153],"(3D)":[154],"outgrowth":[157],"assay,":[158],"phenotype":[160],"driven":[161],"by":[162],"disruption":[163],"Dll4-Notch":[166,226],"axis.":[168],"contrast,":[170],"two-dimensional":[173],"cell-fibroblast":[175],"coculture":[176],"model,":[177],"potent":[181,223],"inhibitor":[182],"formation.":[185],"vivo,":[187],"shows":[189],"activity":[190],"angiogenesis":[196],"assay":[197],"promoting":[198],"reducing":[203],"number":[205],"vessels":[207],"with":[208],"smooth":[209],"muscle":[210],"actin-positive":[211],"mural":[212],"cells":[213],"coverage.":[214],"Collectively,":[215],"data":[217],"show":[218],"modulator":[224],"pathway.":[228]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":6},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":7},{"year":2014,"cited_by_count":7},{"year":2013,"cited_by_count":6}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}